Gilead to face HIV antitrust claims


Rory O'Neill

Gilead to face HIV antitrust claims

chrisdorney /

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

Gilead Sciences, Bristol-Myers Squibb, Japan Tobacco, Johnson & Johnson, HIV, cART, antitrust, competition

More on this story

Gilead hit with antitrust suit over HIV drugs